Abstract 2065P
Background
Beyond the diagnosis, multiple situations during the natural history of cancer can be pointed out as stressful and hard to convey. The first Medical Oncology appointment is crucial and comprehensive, where patients are invited to understand their diagnosis and grasp the prognostic consequences of cancer and its treatment. Strategies to elicit information while meeting patients’ needs are required to overcome the potentially challenging moment, improve clinical outcomes and promote safe, high-quality, patient-centred care. This study evaluated the communication preferences at the first medical oncology approach.
Methods
A total of 169 cancer patients from a Portuguese Medical Oncology department answered the C-FAQ (Communication in first medical oncology appointment questionnaire), a survey representing the SPIKES and MPP (Measure of Patients’ Preferences) protocols asking about preferences regarding Content (what and how much information is told), Facilitation (where and when the information is conveyed), and Support (emotional support during the interaction) elements of communication and patient’s assign to these items.
Results
The Content elements (M=3.69, SD=0.35) were mentioned as the most important when compared with Facilitation (M=3.56, SD=0.39), t(30.13) = 17.38, p < .001, or Support (M=3.46, SD=0.44), t(24.14) = 7.12 p < .001. The physician’s knowledge, honesty and being given clear information about cancer and treatment were the areas of greatest importance. Facilitation was considered more important than Support, t(24.14) = 16.42, p < .001. Globally, all items were mostly evaluated as “very important”, Mdn 65.85% (11.525).
Conclusions
All communication components should be considered during the dialogue in this context. Medical teams should overcome barriers by learning skills to communicate with patients and promote engagement. More research is required to understand the complexity of the triad patient, physician, and family and address how patients’ preferences can be met in a demanding clinical atmosphere.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Professor Doutor Fernando Fonseca.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06